<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124343">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01857973</url>
  </required_header>
  <id_info>
    <org_study_id>CEP273</org_study_id>
    <nct_id>NCT01857973</nct_id>
  </id_info>
  <brief_title>Overnight Closed Loop Study in U.S.</brief_title>
  <acronym>OCL</acronym>
  <official_title>In-Clinic Feasibility Study to Observe the Overnight Closed Loop System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter feasibility study.  Up to 85 subjects will be enrolled in the study.
      The goal of the study is to demonstrate that the Overnight Closed Loop (OCL) System is safe
      to be used in an even larger study outside of hospital.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects that have met eligibility criteria will be assigned to one of the 5 different
      groups (ie. Exploratory A Group, Exploratory B Group, Phase 1A Group, Phase 1B Group, Phase
      2 Group). Up to 6 investigational centers will be used during this study.

      There is no statistically powered study hypothesis testing.

      The investigational centers will be encouraged to include subjects of different ethnicities
      including Hispanic, Native American, and African-American.

      The study is anticipated to last no more than 12 months from investigational center
      initiation to finalization of all data entry and monitoring procedures. Subjects are
      expected to participate for approximately 1- 2 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>No primary endpoint, only descriptive endpoints for Overnight Closed Loop (OCL) system performance</measure>
    <time_frame>in one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>clinical data obtained from this study will demonstrate system performance</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>CompletedExploratory A Evaluation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>using OCL System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exploratory B Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>using Revel 2.0 Insulin Pump</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>using OCL System - procedure 1A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1B Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>using OCL System - procedure 1B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>using OCL System - procedure 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCL System</intervention_name>
    <description>The Overnight Closed Loop System is an investigational device intended for closed loop control of blood glucose during the night.</description>
    <arm_group_label>CompletedExploratory A Evaluation</arm_group_label>
    <arm_group_label>Exploratory B Group</arm_group_label>
    <arm_group_label>Phase 1A Group</arm_group_label>
    <arm_group_label>Phase 1B Group</arm_group_label>
    <arm_group_label>Phase 2 Group</arm_group_label>
    <other_name>Overnight Closed Loop System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is 22-75 years of age at time of screening

          2. A clinical diagnosis of type 1 diabetes as determined by either medical record or
             source documentation from qualified individual to make medical diagnosis

             Exclusion Criteria that are Based on Demands of In-Clinic Study Procedures :

          3. Pump therapy for greater than 6 months with use of real time CGM for any period of
             time (ie. one day) 3 months prior to screening

          4. Adequate venous access as assessed by investigator or appropriate staff

          5. Subject should have an established insulin carbohydrate and insulin sensitivity
             ratio.

          6. Subject reports at the time of screening that their average fasting glucose is 60
             mg/dL - 200 mg/dL

          7. Subject reports at the time of screening that their average total daily insulin dose
             is 15 units - 110 units.  (Insulin pump memory for this information may be used)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Lee, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yiming Deng</last_name>
    <phone>818-576-5472</phone>
    <email>yiming.deng@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Troub</last_name>
    <phone>818-576-3142</phone>
    <email>thomas.troub@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AMCR Institute, Inc. 700 West El Norte Parkway, Suite 201</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Bedolla</last_name>
      <phone>760-466-1526</phone>
      <email>lbedolla@amcrinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Timothy Bailey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center, 1775 Aurora Court, A140</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dawn White</last_name>
      <phone>303-724-6770</phone>
      <email>Dawn.white@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Satish Garg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine, 2 Church Street South, Suite 404</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lori Carria</last_name>
      <phone>203-737-3595</phone>
      <email>loria.carria@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Stuart Weinzimer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center, One Joslin Place</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Astrid Rogert</last_name>
      <phone>617-264-2767</phone>
      <email>astrid.castillo@joslin.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Howard Wolpert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia, 617 West Main Street, 4th Floor</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Oliveri</last_name>
      <phone>434-982-0602</phone>
      <email>MC7M@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Stacey Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research, 723 SW 10th Street, Suite 100</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Hughes</last_name>
      <phone>425-271-1720</phone>
      <phone_ext>15</phone_ext>
      <email>khughes@rainier-research.com</email>
    </contact>
    <investigator>
      <last_name>Ron Brazg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>May 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OCL</keyword>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Sensor</keyword>
  <keyword>Artificial calibration error</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
